NZ586357A - Antibodies to the pcrv antigen of pseudomonas aeruginosa - Google Patents

Antibodies to the pcrv antigen of pseudomonas aeruginosa

Info

Publication number
NZ586357A
NZ586357A NZ586357A NZ58635708A NZ586357A NZ 586357 A NZ586357 A NZ 586357A NZ 586357 A NZ586357 A NZ 586357A NZ 58635708 A NZ58635708 A NZ 58635708A NZ 586357 A NZ586357 A NZ 586357A
Authority
NZ
New Zealand
Prior art keywords
sequence
pseudomonas aeruginosa
antibodies
pcrv
cdr3
Prior art date
Application number
NZ586357A
Other languages
English (en)
Inventor
Christopher R Bebbington
Kenneth Luehrsen
Geoffrey T Yarranton
Mark Baer
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of NZ586357A publication Critical patent/NZ586357A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ586357A 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa NZ586357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
NZ586357A true NZ586357A (en) 2012-10-26

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ586357A NZ586357A (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Country Status (15)

Country Link
US (3) US8044181B2 (https=)
EP (1) EP2220117A2 (https=)
JP (1) JP5781765B2 (https=)
KR (1) KR20100097719A (https=)
CN (1) CN101910197B (https=)
AU (1) AU2008333985B2 (https=)
BR (1) BRPI0819598A2 (https=)
CA (1) CA2706732A1 (https=)
EA (1) EA201000903A1 (https=)
IL (1) IL206036A0 (https=)
MX (1) MX2010005871A (https=)
NZ (1) NZ586357A (https=)
SG (1) SG186017A1 (https=)
WO (1) WO2009073631A2 (https=)
ZA (1) ZA201003852B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
JP5444553B2 (ja) * 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
BRPI0906810A2 (pt) 2008-01-10 2019-10-01 Shionogi & Co anticorpo contra pcrv
WO2010091189A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
CN104119437A (zh) * 2009-03-11 2014-10-29 盐野义制药株式会社 具有抗绿脓杆菌作用的人源化PcrV抗体
CA2784033A1 (en) * 2009-12-22 2011-07-21 Kalobios Pharmaceuticals, Inc. A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
SG11201404532XA (en) 2012-03-02 2014-08-28 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
EP3288974B1 (en) * 2015-05-01 2020-11-04 Inhibrx, Inc. Type iii secretion system targeting molecules
NZ777930A (en) 2015-07-16 2025-05-02 Inhibrx Biosciences Inc Multivalent and multispecific dr5-binding fusion proteins
EA201892525A1 (ru) 2016-05-05 2019-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Конструкции днк-антител для применения против pseudomonas aeruginosa
SG11202008926RA (en) 2018-03-14 2020-10-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
CN112955463B (zh) 2018-08-01 2024-07-05 赛福伦有限责任公司 抗cxcr2抗体及其用途
SG11202112462RA (en) * 2019-06-11 2021-12-30 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US134098A (en) * 1872-12-17 Improvement in gage-cocks
US108565A (en) * 1870-10-25 Improvement in snow-plows
US225552A (en) * 1880-03-16 Disintegrating-mill
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
CA2267620A1 (en) 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
DE69930166T2 (de) * 1998-11-25 2006-12-14 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DK1353688T3 (da) * 2001-01-26 2007-04-10 Mcw Res Found Inc Fremgangsmåde og sammensætninger til immunisering med Psedomonas V-antigenet
CA2374027A1 (en) * 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1479695B1 (en) * 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20060134098A1 (en) * 2004-11-16 2006-06-22 Kalobios, Inc. Immunoglobulin variable region cassette exchange
WO2006122822A2 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CA2613691A1 (en) 2005-07-05 2007-01-11 Baker Medical Research Institute Anticoagulation agent and uses thereof
US20080317710A1 (en) 2006-02-22 2008-12-25 University Of Zurich Methods For Treating Autoimmune or Demyelinating Diseases
AR061171A1 (es) 2006-06-02 2008-08-06 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch)
CN101573383B (zh) 2006-06-21 2015-05-13 肿瘤疗法科学股份有限公司 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途

Also Published As

Publication number Publication date
WO2009073631A3 (en) 2009-09-24
EA201000903A1 (ru) 2011-02-28
ZA201003852B (en) 2014-11-26
IL206036A0 (en) 2010-11-30
JP2011505381A (ja) 2011-02-24
CN101910197A (zh) 2010-12-08
WO2009073631A2 (en) 2009-06-11
KR20100097719A (ko) 2010-09-03
CN101910197B (zh) 2014-09-24
MX2010005871A (es) 2010-06-09
EP2220117A2 (en) 2010-08-25
US8044181B2 (en) 2011-10-25
US20120020986A1 (en) 2012-01-26
JP5781765B2 (ja) 2015-09-24
BRPI0819598A2 (pt) 2017-05-09
AU2008333985A1 (en) 2009-06-11
US20150030614A1 (en) 2015-01-29
US8877191B2 (en) 2014-11-04
CA2706732A1 (en) 2009-06-11
US20090191186A1 (en) 2009-07-30
SG186017A1 (en) 2012-12-28
AU2008333985B2 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
NZ586357A (en) Antibodies to the pcrv antigen of pseudomonas aeruginosa
MY200988A (en) CD3 Binding Antibodies
NZ712765A (en) Antibodies that bind csf1r
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ703035A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ595235A (en) Compositions and methods for increasing muscle growth
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
NZ602294A (en) Monoclonal antibodies against c-met
NZ628923A (en) Targeted binding agents against b7-h1
AU2010234031A8 (en) Trivalent, bispecific antibodies
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
NZ607711A (en) Antibodies directed to her-3 and uses thereof
NZ602040A (en) Anti-lrp6 antibodies
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ626269A (en) Anti-phf-tau antibodies and their uses
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ605980A (en) Anti-fap antibodies and methods of use
NZ616382A (en) Antibodies specific to cadherin-17

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: KALOBIOS PHARMACEUTICALS, INC., US

Free format text: OLD OWNER(S): KALOBIOS PHARMACEUTICALS, INC.; KENNETH LUEHRSEN; GEOFFREY T. YARRANTON; CHRISTOPHER R. BEBBINGTON; MARK BAER

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 DEC 2015 BY CPA GLOBAL

Effective date: 20130313

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 DEC 2016 BY CPA GLOBAL

Effective date: 20151016

LAPS Patent lapsed